The SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date. This data reinforces the outstanding safety of WATCHMAN FLX with a 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success in >16,000 real-world NVAF patients.1
Heart Rhythm Meta-Analysis
The Meta-Analysis is the largest comparison of peri-procedural success and short-term outcomes of WATCHMAN FLX vs Amplatzer Amulet reveals superior procedural safety, higher procedural success, and better LAA closure with WATCHMAN FLX.2
SEAL FLX is the first study to compare Amulet exclusively to WATCHMAN FLX and the results demonstrated that statistically superior complete occlusion* was achieved when using WATCHMAN FLX.3
Trials Currently Enrolling
With over 150,000 patients implanted with the WATCHMAN platform, CHAMPION-AF extends Boston Scientific’s LAAC leadership by evaluating WATCHMAN FLX™ as a safe and effective first-line option versus NOAC to reduce stroke risk.
Clinical Trial Results
* Complete LAA occlusion defined as no visible peri-device leak (PDL) and absence of contrast patency in the distal LAA (LAA/left atrium Hounsfield ratio <0.25)
1. Late Breaking Clinical Trial at CRT 2022, Presented by Dr. Samir Kapadia
2. Della Rocca, D., Magnocavallo, M., Gianni, C., Horton, R., Biase, L., Natale, A., Procedural and short-term follow-up outcomes of Amplatzer Amulet Occluder versus Watchman FLX Device: A Meta-Analysis, Heart Rhythm, February 2022, https://doi.org/10.1016/j.hrthm.2022.02.007.
3. Korsholm-K et al.; TCT 2021